Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1827401 · FYE Sep 30 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $71.96Day +0.07%1Y +112.5%Off 52W high −41.9%Vol (1Y) 72.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,162 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Days to cover3.1d |
| Top-10 13F concentration67.0% |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-CAD 12.2M |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (CAD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−7.8% |
| 1Y+112.5% |
| 3Y+1721.8% |
| Since incept. (ann.)+28.0% |
Total return through 2026-07-28 · series begins 2021-11-29. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)72.1% |
| Ann. volatility (3Y)850.0% |
| Sharpe (1Y)1.42 |
| Sharpe (3Y)0.66 |
| Max drawdown (1Y)−38.4% |
| Max drawdown (3Y)−77.0% |
| Beta (3Y vs SPY)−17.15 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 1.3M | $94M | — | +11.1% |
| Cormorant Asset Management, LP | 1.1M | $77M | — | +0.0% |
| BlackRock, Inc. | 621,933 | $45M | — | +57.8% |
| Vivo Capital, LLC | 557,172 | $41M | — | +11.1% |
| BRAIDWELL LP | 539,708 | $39M | — | +66.4% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 495,743 | $36M | — | +25.3% |
| Vestal Point Capital, LP | 492,319 | $36M | — | new |
| Driehaus Capital Management LLC | 432,515 | $32M | — | +60.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
No reported quarters on file for DRUG.
